Novo Nordisk Stock Rises on Potential Federal Support for Weight-Loss Drugs
Novo Nordisk's stock climbed more than 2% Friday following reports of a potential federal program to cover weight-loss medications. The Washington Post revealed plans by the TRUMP administration to launch an experimental five-year initiative under Medicaid and Medicare Part D, expanding coverage for obesity treatments like Wegovy and Zepbound.
Currently, Medicare only reimburses these drugs for type 2 diabetes patients. The policy shift could unlock massive demand—Medicare and Medicaid collectively represent the largest healthcare payers in the U.S. market. Novo Nordisk declined to comment, but the Danish pharma giant stands to benefit disproportionately as the market leader in GLP-1 therapies.